Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy

Genomics

Volumn 106, Issue 6, 2015, Pages 348-354

  Pfütze, Katrin ^a,b   Benner, Axel ^a   Hoffmeister, Michael ^a   Jansen, Lina ^a   Yang, Rongxi ^a,b   Bläker, Hendrik ^b   Herpel, Esther ^a,b   Ulrich, Alexis ^b,c   Ulrich, Cornelia M ^a   Chang Claude, Jenny ^a   Brenner, Hermann ^a   Burwinkel, Barbara ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Division of Molecular oncology   (Germany)

Author keywords

5 FU; Chemotherapy; Colorectal cancer; DNA methylation; HYAL2; Predictive marker; Prognostic marker

Indexed keywords

FLUOROURACIL; FOLIC ACID; HYALURONOGLUCOSAMINIDASE; HYALURONOGLUCOSAMINIDASE 2; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; CELL ADHESION MOLECULE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HYAL2 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; CPG ISLAND; DNA ISOLATION; DNA METHYLATION; EARLY DIAGNOSIS; EXON; FEMALE; GENE EXPRESSION REGULATION; GENE LOCUS; HUMAN; HUMAN TISSUE; HYLA2 GENE; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; SMOKING; TUMOR GENE; AGED; COLONIC NEOPLASMS; DISEASE FREE SURVIVAL; FOLLOW UP; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; REGRESSION ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CELL ADHESION MOLECULES; COLONIC NEOPLASMS; CPG ISLANDS; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GPI-LINKED PROTEINS; HUMANS; HYALURONOGLUCOSAMINIDASE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 84947942188     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2015.10.002     Document Type: Article

References (51)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. Ca Cancer J. Clin. 2008, 58:71-96.
2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2015, 65:5-29.
3. Jass J.R. Molecular heterogeneity of colorectal cancer: Implications for cancer control. Surg. Oncol. 2007, 16(1):S7-S9.
4. Graham J.S., Cassidy J. Adjuvant therapy in colon cancer. Expert. Rev. Anticancer. Ther. 2012, 12:99-109.
5. Van Rijnsoever M., Elsaleh H., Joseph D., Mccaul K., Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 2003, 9:2898-2903.
6. Benson A.B., Schrag D., Somerfield M.R., Cohen A.M., Figueredo A.T., Flynn P.J., Krzyzanowska M.K., Maroun J., Mcallister P., Van Cutsem E., Brouwers M., Charette M., Haller D.G. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 2004, 22:3408-3419.
7. Wu X., Zhang J., He X., Wang C., Lian L., Liu H., Wang J., Lan P. Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. J. Gastrointest. Surg. 2012, 16:646-655.
8. Yi J.M., Dhir M., Van Neste L., Downing S.R., Jeschke J., Glockner S.C., de Freitas Calmon M., Hooker C.M., Funes J.M., Boshoff C., Smits K.M., van Engeland M., Weijenberg M.P., Iacobuzio-Donahue C.A., Herman J.G., Schuebel K.E., Baylin S.B., Ahuja N. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin. Cancer Res. 2011, 17:1535-1545.
9. Iacopetta B., Kawakami K., Watanabe T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?. Int. J. Clin. Oncol. 2008, 13:498-503.
10. Walther A., Johnstone E., Swanton C., Midgley R., Tomlinson I., Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat. Rev. Cancer 2009, 9:489-499.
11. Weber M., Davies J.J., Wittig D., Oakeley E.J., Haase M., Lam W.L., Schubeler D. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet. 2005, 37:853-862.
12. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8:286-298.
13. Matou-Nasri S., Gaffney J., Kumar S., Slevin M. Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and gamma-adducin. Int. J. Oncol. 2009, 35:761-773.
14. Lokeshwar V.B., Obek C., Soloway M.S., Block N.L. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res. 1997, 57:773-777.
15. Lepperdinger G., Strobl B., Kreil G. HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity. J. Biol. Chem. 1998, 273:22466-22470.
16. dela Motte C., Nigro J., Vasanji A., Rho H., Kessler S., Bandyopadhyay S., Danese S., Fiocchi C., Stern R. Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines. Am. J. Pathol. 2009, 174:2254-2264.
17. Slevin M., Kumar S., Gaffney J. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. J. Biol. Chem. 2002, 277:41046-41059.
18. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 2004, 4:528-539.
19. Bouga H., Tsouros I., Bounias D., Kyriakopoulou D., Stavropoulos M.S., Papageorgakopoulou N., Theocharis D.A., Vynios D.H. Involvement of hyaluronidases in colorectal cancer. BMC Cancer 2010, 10:499.
20. Ropponen K., Tammi M., Parkkinen J., Eskelinen M., Tammi R., Lipponen P., Agren U., Alhava E., Kosma V.M. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res. 1998, 58:342-347.
21. Irizarry R.A., Ladd-Acosta C., Wen B., Wu Z., Montano C., Onyango P., Cui H., Gabo K., Rongione M., Webster M., Ji H., Potash J.B., Sabunciyan S., Feinberg A.P. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 2009, 41:178-186.
22. Yang R., Pfutze K., Zucknick M., Sutter C., Wappenschmidt B., Marme F., Qu B., Cuk K., Engel C., Schott S., Schneeweiss A., Brenner H., Claus R., Plass C., Bugert P., Hoth M., Sohn C., Schmutzler R., Bartram C.R., Burwinkel B. DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood. Int. J. Cancer 2015, 136(8):1845-1855.
23. M. Maierthaler, M. Kriegsmann, C. Peng, S. Jauch, A. Szabo, M. Wallwiener, J. Rom, C. Sohn, A. Schneeweiss, H.P. Sinn, R. Yang, and B. Burwinkel, S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer. Exp. Mol. Pathol. 99 180-7.
24. Lilla C., Verla-Tebit E., Risch A., Jager B., Hoffmeister M., Brenner H., Chang-Claude J. Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol. Biomark. Prev. 2006, 15:99-107.
25. Brenner H., Chang-Claude J., Seiler C.M., Rickert A., Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann. Intern. Med. 2011, 154:22-30.
26. Breitling L.P., Salzmann K., Rothenbacher D., Burwinkel B., Brenner H. Smoking, F2RL3 Methylation and Prognosis in Stable Coronary Heart Disease 2012.
27. Dunkler D., Schemper M., Heinze G. Gene selection in microarray survival studies under possibly non-proportional hazards. Bioinformatics 2010, 26:784-790.
28. Schemper M., Smith T.L. A note on quantifying follow-up in studies of failure time. Control. Clin. Trials 1996, 17:343-346.
29. Heyn H., Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat. Rev. Genet. 2012, 13(10):679-692.
30. Dallol A., Al-Maghrabi J., Buhmeida A., Gari M.A., Chaudhary A.G., Schulten H.J., Abuzenadah A.M., Al-Ahwal M.S., Sibiany A., Al-Qahtani M.H. Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer. Cancer Epidemiol. Biomark. Prev. 2012, 21:2069-2075.
31. Nagaraju G.P., El-Rayes B.F. SPARC and DNA methylation: possible diagnostic and therapeutic implications in gastrointestinal cancers. Cancer Lett. 2013, 328:10-17.
32. Hisamuddin I.M., Wehbi M.A., Yang V.W. Pharmacogenetics and diseases of the colon. Curr. Opin. Gastroenterol. 2007, 23:60-66.
33. Nagasaka T., Sharp G.B., Notohara K., Kambara T., Sasamoto H., Isozaki H., Macphee D.G., Jass J.R., Tanaka N., Matsubara N. Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. Clin. Cancer Res. 2003, 9:5306-5312.
34. 6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. Oncol. Rep. 2007, 17:1461-1467.
35. Coppede F., Lopomo A., Spisni R., Migliore L. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J. Gastroenterol. 2014, 20:943-956.
36. J.M. Ng, and J. Yu, Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int. J. Mol. Sci. 16 2472-96.
37. Sousa J.F., Ham A.J., Whitwell C., Nam K.T., Lee H.J., Yang H.K., Kim W.H., Zhang B., Li M., Lafleur B., Liebler D.C., Goldenring J.R. Proteomic profiling of paraffin-embedded samples identifies metaplasia-specific and early-stage gastric cancer biomarkers. Am. J. Pathol. 2012, 181:1560-1572.
38. How Kit A., Nielsen H.M., Tost J. DNA methylation based biomarkers: practical considerations and applications. Biochimie 2012, 94:2314-2337.
39. Lepperdinger G., Mullegger J., Kreil G. Hyal2-less active, but more versatile?. Matrix Biol. 2001, 20:509-514.
40. Fallik D., Borrini F., Boige V., Viguier J., Jacob S., Miquel C., Sabourin J.C., Ducreux M., Praz F. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 2003, 63:5738-5744.
41. Benatti P., Gafa R., Barana D., Marino M., Scarselli A., Pedroni M., Maestri I., Guerzoni L., Roncucci L., Menigatti M., Roncari B., Maffei S., Rossi G., Ponti G., Santini A., Losi L., Di Gregorio C., Oliani C., Ponz De Leon M., Lanza G. Microsatellite instability and colorectal cancer prognosis. Clin. Cancer Res. 2005, 11:8332-8340.
42. Dehan E., Ben-Dor A., Liao W., Lipson D., Frimer H., Rienstein S., Simansky D., Krupsky M., Yaron P., Friedman E., Rechavi G., Perlman M., Aviram-Goldring A., Izraeli S., Bittner M., Yakhini Z., Kaminski N. Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer 2007, 56:175-184.
43. Ghosh S., Ghosh A., Maiti G.P., Alam N., Roy A., Roy B., Roychoudhury S., Panda C.K. Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: correlation with progression and prognosis. Int. J. Cancer 2008, 123:2594-2604.
44. Ching H.C., Naidu R., Seong M.K., Har Y.C., Taib N.A. Integrated analysis of copy number and loss of heterozygosity in primary breast carcinomas using high-density SNP array. Int. J. Oncol. 2011, 39:621-633.
45. Duterme C., Mertens-Strijthagen J., Tammi M., Flamion B. Two novel functions of hyaluronidase-2 (Hyal2) are formation of the glycocalyx and control of CD44-ERM interactions. J. Biol. Chem. 2009, 284:33495-33508.
46. Saito T., Kawana H., Azuma K., Toyoda A., Fujita H., Kitagawa M., Harigaya K. Fragmented hyaluronan is an autocrine chemokinetic motility factor supported by the HAS2-HYAL2/CD44 system on the plasma membrane. Int. J. Oncol. 2011, 39:1311-1320.
47. Paiva P., Van Damme M.P., Tellbach M., Jones R.L., Jobling T., Salamonsen L.A. Expression patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a role for hyaluronan in the progression of endometrial cancer. Gynecol. Oncol. 2005, 98:193-202.
48. Drewinko B., Patchen M., Yang L.Y., Barlogie B. Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res. 1981, 41:2328-2333.
49. Hsu L.J., Schultz L., Hong Q., Van Moer K., Heath J., Li M.Y., Lai F.J., Lin S.R., Lee M.H., Lo C.P., Lin Y.S., Chen S.T., Chang N.S. Transforming growth factor beta1 signaling via interaction with cell surface Hyal-2 and recruitment of WWOX/WOX1. J. Biol. Chem. 2009, 284:16049-16059.
50. Azuma M., Motegi K., Aota K., Yamashita T., Yoshida H., Sato M. TGF-beta1 inhibits NF-kappaB activity through induction of IkappaB-alpha expression in human salivary gland cells: a possible mechanism of growth suppression by TGF-beta1. Exp. Cell Res. 1999, 250:213-222.
51. Aota K., Azuma M., Yamashita T., Tamatani T., Motegi K., Ishimaru N., Hayashi Y., Sato M. 5-Fluorouracil induces apoptosis through the suppression of NF-kappaB activity in human salivary gland cancer cells. Biochem. Biophys. Res. Commun. 2000, 273:1168-1174.